Peter Finan Ph.D

Peter Finan Ph.D General Information

Biography

Dr. Peter Finan serves as Non-Executive Chairman at Epsilogen. He serves as Board Member at Epidarex Capital. He serves as Chief Executive Officer & Board Member at AdoRx Therapeutics. He serves as Partner & Board Member at Epidarex Exeed. He served as a Board Member at Clyde Biosciences. He serves as a Board Member at Curve Therapeutics and Leucid Bio. He also serves as Supervisory Board Observer at Topas Therapeutics. He served as a Board Observer at Eternygen and IGEM Therapeutics. He served as a Head of Biology at Karus Therapeutics. He was appointed Head of Biology at Karus in 2014 following an extensive career in the pharmaceutical industry, from target discovery through to early clinical development in oncology and inflammatory disease. He joined Karus from Novartis, where he held a number of senior roles over a period of 16 years, during which time he worked on, amongst others, the PI3K pathway. He received both his degree in Biochemistry and Microbiology and his Ph.D. in Biochemistry from the University of Leeds.